Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Guangzhou Sinogen Pharmaceutical Co. Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is concentrated under 1 distinct examiner and 1 distinct art unit. This suggests a targeted approach to securing intellectual property for its pharmaceutical developments, which are being reviewed within a single specialized division of the USPTO.
ALEXANDER W NICOL is the busiest examiner for the company, overseeing 1 pending office action. Because the portfolio involves only 1 distinct examiner and 1 distinct art unit, the company's prosecution results are currently dependent on a single point of contact. The 1 pending office action represents the entirety of the company's active matters in the Biotechnology & Pharmaceuticals sector. Practitioners should focus on the specific examination history of the 1 distinct examiner to better predict the timeline and potential hurdles for this single pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICOL, ALEXANDER W | 1 | 42.7% | +43.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18012877 | APPLICATION OF METHIONINASE GENE THERAPY IN TREATMENT OF MALIGNANT TUMOR | NICOL, ALEXANDER W | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18012877 | APPLICATION OF METHIONINASE GENE THERAPY IN TREATMENT OF MALIGNANT TUMOR | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | — | Pending | Dec 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuangzhou Sinogen Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexander W Nicol has the most, with 1 of Guangzhou Sinogen Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
